Author:
Atay Julie K.,Fanikos John,Barnes Geoffrey D.,Ehle Michael,Coatney John,Piazza Gregory,Froehlich James B.,Goldhaber Samuel Z.
Subject
Cardiology and Cardiovascular Medicine
Reference13 articles.
1. The new oral anticoagulants;Garcia;Blood,2010
2. Dabigatran versus warfarin in patients with atrial fibrillation;Connolly;N Engl J Med,2009
3. Dabigatran challenges warfarin's superiority for stroke prevention in atrial fibrillation;Schwartz;Stroke,2010
4. New oral anticoagulants should not be used as first line agents to prevent thromboembolism in patients with atrial fibrillation;Ansell;Circulation,2012
5. United States Food and Drug Administration. Pradaxa (Dabigatran Etexilate Mesylate): Drug Safety Communication—Safety Review of Post-Market Reports of Serious Bleeding Events. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm282820.htm. Accessed on November 13, 2012.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献